Pediatrix Medical Group, Inc. (NYSE:MD) Receives Consensus Rating of “Moderate Buy” from Brokerages

by · The Cerbat Gem

Shares of Pediatrix Medical Group, Inc. (NYSE:MD – Get Free Report) have received an average rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $21.00.

Several brokerages recently issued reports on MD. UBS Group upped their target price on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Truist Financial upped their price objective on Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Wall Street Zen raised Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 4th. Zacks Research raised Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th.

View Our Latest Stock Report on MD

Insiders Place Their Bets

In other Pediatrix Medical Group news, Director Michael A. Rucker sold 10,478 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $23.00, for a total transaction of $240,994.00. Following the completion of the sale, the director directly owned 59,101 shares in the company, valued at $1,359,323. This represents a 15.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Laura A. Linynsky sold 10,000 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $21.65, for a total value of $216,500.00. Following the transaction, the director directly owned 32,232 shares in the company, valued at $697,822.80. This trade represents a 23.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 43,478 shares of company stock valued at $972,924 over the last three months. Insiders own 0.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. bought a new stake in Pediatrix Medical Group during the 4th quarter valued at approximately $37,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in shares of Pediatrix Medical Group by 15.8% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 17,358 shares of the company’s stock valued at $371,000 after purchasing an additional 2,369 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Pediatrix Medical Group in the fourth quarter worth $13,613,000. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Pediatrix Medical Group by 14.9% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 36,598 shares of the company’s stock valued at $783,000 after buying an additional 4,735 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its position in shares of Pediatrix Medical Group by 8.9% in the 4th quarter. Exchange Traded Concepts LLC now owns 77,107 shares of the company’s stock worth $1,649,000 after buying an additional 6,276 shares during the period. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Price Performance

Shares of MD traded down $0.82 during trading hours on Friday, reaching $21.85. 656,774 shares of the company’s stock traded hands, compared to its average volume of 601,021. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The firm’s 50 day simple moving average is $22.48 and its 200-day simple moving average is $18.17. The stock has a market cap of $1.88 billion, a PE ratio of 11.50 and a beta of 0.73. Pediatrix Medical Group has a 12 month low of $11.84 and a 12 month high of $24.99.

Pediatrix Medical Group (NYSE:MD – Get Free Report) last announced its earnings results on Monday, November 3rd. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.21. The business had revenue of $492.88 million during the quarter, compared to analyst estimates of $476.45 million. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. Pediatrix Medical Group’s revenue for the quarter was down 3.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.44 earnings per share. Equities analysts expect that Pediatrix Medical Group will post 1.38 EPS for the current year.

Pediatrix Medical Group Company Profile

(Get Free Report)

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.

Featured Articles